Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

Fineline Cube Jan 2, 2024

Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...

Company Deals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

Fineline Cube Dec 29, 2023

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B...

Company Drug

Boan Biotech Secures FDA Orphan Drug Designations for Pancreatic Cancer Treatments

Fineline Cube Dec 29, 2023

China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate...

Company Deals

Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets

Fineline Cube Dec 29, 2023

Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...

Company Drug

Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma

Fineline Cube Dec 29, 2023

Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and...

Company Drug

FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision

Fineline Cube Dec 29, 2023

The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...

Company Drug

Lepu Biotechnology Completes Enrollment for Phase IIb Trial of MRG003 in Nasopharyngeal Carcinoma

Fineline Cube Dec 29, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced the completion of subject...

Company Medical Device

Sino Medical Secures Approvals for Key Coronary Devices in Taiwan, India, and Uzbekistan

Fineline Cube Dec 29, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical device company, has announced that...

Company Drug

Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer

Fineline Cube Dec 29, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...

Company Deals

IVD Medical Ends Strategic Partnership with Japan’s Sysmex in Coagulation Products

Fineline Cube Dec 29, 2023

IVD Medical Holding Ltd (HKG: 1931), a China-based in vitro diagnostic (IVD) specialist, has announced...

Company Drug

Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Dec 29, 2023

Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its...

Company Deals

Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio

Fineline Cube Dec 28, 2023

Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...

Company Drug

Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment

Fineline Cube Dec 28, 2023

Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...

Company Deals

CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies

Fineline Cube Dec 28, 2023

China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...

Company Medical Device

Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen

Fineline Cube Dec 28, 2023

Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing...

Company Drug

Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access

Fineline Cube Dec 28, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...

Company

Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges

Fineline Cube Dec 28, 2023

Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...

Company Deals

TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical

Fineline Cube Dec 28, 2023

Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Company Deals

Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors

Fineline Cube Dec 28, 2023

Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...

Posts pagination

1 … 360 361 362 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.